Scienture reports preliminary Q3 2026 revenue of about $1.22 million
The company said unaudited preliminary revenue grew 256% sequentially.
Story updates
12:07:02 PM UTC
SquawkNews
Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growthArbli™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial…
12:07:32 PM UTC
SquawkNews
SCIENTURE HOLDINGS, INC. reported preliminary, unaudited Q3 2026 revenue of approximately $1.22M, up 256% from ~$344K in Q2, driven by REZENOPY’s August launch and higher Arbli sales.Material DetailsContext by AI AnalystThis is an early-stage revenue ramp, with growth driven by a new product launch…